• Technology
  • DuplexSeq™ Kits
    • AML Assay
    • Mutagenesis Assay
    • Custom
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
    • Investors
  • Contact

Meet with TwinStrand at the SOT 2023 Annual Meeting in Nashville, TN
Presentation: 9:00 AM, 3/22, Room 101C | Posters: 3604, 3606, 3244

Schedule a Meeting
TwinStrand Biosciences
  • Technology
  • DuplexSeq™ Kits
    • AML Assay
    • Mutagenesis Assay
    • Custom
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
    • Investors
  • Contact

AML MRD Detection Assay

 

Next-generation sequencing (NGS) is a powerful emerging method for detecting residual acute myeloid leukemia (AML) after treatment. However, current methods produce an abundance of sequencing errors which obscure low-frequency leukemia-defining mutations.

 

The TwinStrand Duplex Sequencing™ AML MRD assay is orders of magnitude more sensitive and specific than other NGS-based MRD assays, offering unprecedented opportunities for clinical research and drug development.

 

  • >100-fold higher resolution than other error-corrected NGS methods
  • The 29 gene, 58kb panel encompasses loci mutated in 90%-95% of adult AML patients
  • Assay enables sub-1/10,000 limit of detection anywhere in target region

 

Download Data Sheet

Duplex Sequencing MRD Technical Performance

 

The TwinStrand Duplex Sequencing AML MRD assay was used to sequence a serially-diluted mixture of AML mutation-containing DNA to a duplex depth >1,000,000x. Target clones were identified to levels <1/100,000 with 100% sensitivity and specificity.
 

Download Data Sheet

Panel Overview

The AML panel encompasses the whole coding region or hotspots in 29 genes recurrently mutated in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Clonal Hematopoiesis (CHIP).

 


 

Request a Quote

Clonal Hematopoiesis

 

Duplex sequencing detects dozens of synchronous CHIP clones per individual with aging.

 

Request a Quote

Scientific Content

 

 


Posters

 

Longitudinal monitoring of pediatric acute myeloid leukemia using duplex sequencing of patient-specific panels reveals ultra-low frequency MRD that marks persistent carcinogenesis and complex clonal evolution

Super CHIP: Duplex Sequencing Reveals Clonal Dynamics in Blood that are Magnitudes more Complex than Previously Recognized

Duplex Sequencing for MRD Detection in Acute Myeloid Leukemia

Redefining “Gold Standard” Ultra-Sensitive Characterization of Commercial DNA Standards with Duplex Sequencing

 


Abstracts

 

Longitudinal monitoring of pediatric acute myeloid leukemia using duplex sequencing of patient-specific panels reveals ultra-low frequency MRD that marks persistent carcinogenesis and complex clonal evolution

Duplex Sequencing for Ultra-Low Frequency Measurable Residual Disease Detection in Adult Acute Myeloid Leukemia

Product Literature


TwinStrand Duplex Sequencing AML-29 MRD Assay Brochure

Have questions about our AML MRD kit?

Contact us

 

TwinStrand Biosciences, Inc.
3131 Elliott Ave, Suite 750 • Seattle, WA 98121 • USA
+1 (877) 202-TWIN

 

For Research Use Only. Not for use in diagnostic procedures.

©2023 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners.  Legal Notices

  




American Society of Hematology (ASH)

December 5-8, 2020 – Virtual

 

Poster Presentation

 

“Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia”

 

Presented by Jake Higgins, Senior Scientist – December 6, 2020 7:00 a.m.-3:30 p.m. PST

 

Conference Website

 

Society of Toxicology (SOT)

March 10-14, 2019 – Baltimore, MD

 

Poster Presentations

 

 

View Poster

 

 

Conference Website

 

AACR Annual Meeting – San Diego, CA

March 29-April 3, 2019

 

Poster Presentations

 

 

View Poster

 

 

View Poster

Presentations by CEO Jesse Salk, MD, PhD – AGBT 2020

Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Dupex Sequencing